TuHURA Biosciences announced that CEO James A. Bianco will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14. The company is focused on developing novel immuno-oncology therapies to overcome resistance to cancer immunotherapy, including their lead drug IFx-2.0 in Phase 3 trials for Merkel Cell Carcinoma. TuHURA is also advancing other candidates targeting immune resistance mechanisms in cancer. The presentation will provide updates on their clinical progress and future plans.
The US-Canada trade conflict escalated as President Trump threatened to ban Canadian airplane maker Bombardier from selling in the US, citing unfair trade practices. Canada responded with retaliatory tariffs on $20 billion of US goods, including stee...
1606 Corp. has signed a non-binding Letter of Intent (LOI) with EthosEnergy O&M to manage operations and maintenance of its planned 55 MW power facility in Lufkin, Texas, aimed at supporting data centers and AI applications. EthosEnergy O&M brings ex...
abrdn Global Infrastructure Income Fund (ASGI) maintains a Hold rating due to challenges in the utility and industrial sectors causing a decline in its net asset value (NAV). The fund offers a well-covered 12% yield, but distribution coverage may wea...
Adia Med has verified it has 361 round-lot shareholders, exceeding Nasdaq Capital Market's minimum requirement of 300 for an initial listing. This milestone is part of Adia Med's ongoing efforts to meet Nasdaq's listing standards, though other criter...
Québec Innovative Materials Corp. (QIMC) has started two large-scale, non-invasive 2D seismic surveys totaling about 78 line-kilometres to explore natural hydrogen in Québec and Nova Scotia. The 36 km survey in Québec is in partnership with the Témis...
